Search

Meet Jaap-Jan “J. J.” Boelens, who joined MSK Kids in 2018 as Chief of the Stem Cell Transplantation and Cell Therapy Service.

… Monday, October 7, 2019 Jaap-Jan “J. J.” Boelens joined MSK Kids in 2018 as Chief of the Stem Cell Transplantation and Cell Therapy Service. Some of our MSK Kids patients asked him the questions they were most curious about. You’re a new doctor here at MSK Kids. Where did you come from? — James, 4 I

Unlike the clinical management of other types of cancer, a multidisciplinary approach is not the established norm for treating skin cancer, resulting in significantly limited opportunities to individualize patient care.

… Thursday, June 14, 2018 Unlike the clinical management of other types of cancer, a multidisciplinary approach is not the established norm for treating skin cancer, resulting in significantly limited opportunities to individualize patient care. A recent study by our group, and set to be published in the

Memorial Sloan Kettering's new chief nurse Tracy Gosselin says she was taken by surprise when she was asked to consider MSK's top nursing job.

… Thursday, May 5, 2022 Tracy Gosselin says she was taken by surprise when she got the call asking her to consider applying for the top nursing job at Memorial Sloan Kettering Cancer Center (MSK).  “I laughed and said, ‘I can give you lots of names,’ ” she recalls. After careful thought and consultation

Memorial Sloan Kettering Cancer Center (MSK) announces the following awards and appointments.

… Thursday, February 29, 2024 Memorial Sloan Kettering Cancer Center (MSK) today announced the following awards and appointments: Yael David Awarded 2024 Alfred P. Sloan Research Fellowship Yael David Yael David, PhD ,  chemical biologist leading  The Yael David Lab  and   Associate Member of the  Chemical

MSK researchers are making important inroads in understanding and treating pancreatic cancer.

… Saturday, January 1, 2022 For Barbara Brigham, being diagnosed with pancreatic cancer in the fall of 2020 was a devastating blow in an already rough year. She had just lost her mother and husband after long illnesses, both needing extensive care. The 74-year-old semiretired librarian from Long Island

Targeting this signal with drugs might be one way to stop cancers from spreading.

… Thursday, July 26, 2018 Summary Scientists from the Sloan Kettering Institute have identified a key step in the process of metastasis, how cancer spreads to other parts of the body. The step is shared across tumor types and suggests a new angle for targeted therapy. In 90% of cancer deaths, what kills

MSK physicians and researchers design and conduct clinical trials that include adolescent and young adult (AYA) cancer patients, ensuring they are not lost between the typical siloes of adult and pediatric cancer trials.

… Monday, September 13, 2021 MSK physicians and researchers design and conduct clinical trials that include adolescent and young adult (AYA) cancer patients, ensuring they are not lost between the typical siloes of adult and pediatric cancer trials. As a result, more AYA patients benefit from an increasing

The US Food and Drug Administration (FDA) has approved the drug larotrectinib for cancers caused by a genetic mutation called a TRK fusion. Today’s decision marks a transformation in the field of precision medicine as this is the first time that an entirely new treatment has received a tumor-agnostic indication at its initial approval, meaning that the drug was approved based on mutation type rather than on where in the body the tumor originated.

… Monday, November 26, 2018 Bottom Line VIDEO | 02:42 Rihanna's Story of Treatment on a Clinical Trial with Larotrectinib Meet Rihanna, who was on a clinical trial with larotrectinib. Video Details The US Food and Drug Administration (FDA) has approved the drug larotrectinib for cancers caused by a genetic

MSK played a central role in the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC)’s landmark decision in April 2024 to accept measurable residual disease (MRD) as an intermediate clinical endpoint for accelerated approval of new drugs and new indications in multiple myeloma clinical trials.

… Thursday, August 8, 2024 A Q&A with MSK Experts  MSK played a central role in the U.S. Food and Drug Administration (FDA)  Oncologic Drugs Advisory Committee (ODAC)’s landmark decision in April 2024 to accept measurable residual disease (MRD) as an intermediate clinical endpoint for accelerated approval

Memorial Sloan Kettering Cancer Center (MSK) is ranked the number one hospital in the world for oncology according to Newsweek’s World’s Best Specialized Hospitals 2026 list.

… Thursday, October 30, 2025 Memorial Sloan Kettering Cancer Center (MSK) is ranked the number one hospital in the world for oncology according to  Newsweek’s   World’s Best Specialized Hospitals 2026 list. “Earning the distinction as the world’s top hospital for oncology is a profound honor that reflects